Ascendis Pharma A (ASND) EBIT (2014 - 2026)
Ascendis Pharma A (ASND) posted EBIT of $29.0 million for Q1 2026, up 152.17% sequentially from $11.5 million in Q4 2025, and up 126.5% YoY from $12.8 million in Q1 2025.
Ascendis Pharma A (ASND) EBIT (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported EBIT for 13 years, with the latest figure at $29.0 million in Q1 2026.
- Quarterly EBIT rose 126.5% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.5 million (down 100.0% YoY) and the FY2025 annual result came in at -$158.6 million, up 46.75% from the prior year.
- EBIT grew to $29.0 million in Q1 2026 per ASND's latest filing, from $11.5 million in the prior quarter.
- Over five years, EBIT peaked at $409.3 billion in Q4 2024 and troughed at -$154.2 million in Q1 2023.
- A 5-year average of $24.0 billion and a median of -$109.6 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT soared 1039121.01% in 2024, then sank 105.32% in 2025.
- Over 5 years, EBIT stood at -$150.4 million in 2022, then surged by 73.8% to -$39.4 million in 2023, then jumped by 1039121.01% to $409.3 billion in 2024, then slumped by 100.0% to $11.5 million in 2025, then surged by 152.17% to $29.0 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered $29.0 million, $11.5 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 29.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.05 Mn |
| Dec 31, 2025 | 11.52 Mn |
| Sep 30, 2025 | 12.86 Mn |
| Jun 30, 2025 | -59.94 Mn |
| Mar 31, 2025 | -109.62 Mn |
| Dec 31, 2024 | 409.27 Bn |
| Sep 30, 2024 | -106.25 Mn |
| Jun 30, 2024 | -143.50 Mn |
| Mar 31, 2024 | -53.39 Mn |
| Dec 31, 2023 | -39.39 Mn |
| Sep 30, 2023 | -146.31 Mn |
| Jun 30, 2023 | -153.36 Mn |
| Mar 31, 2023 | -154.22 Mn |
| Dec 31, 2022 | -150.37 Mn |
| Sep 30, 2022 | -145.70 Mn |
| Jun 30, 2022 | -151.41 Mn |
| Mar 31, 2022 | -143.69 Mn |
| Dec 31, 2021 | -128.79 Mn |
| Sep 30, 2021 | -114.31 Mn |
| Jun 30, 2021 | -141.66 Mn |